Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1648 1671 1672
This examiner grants 69% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19217607 | VECTOR-BASED GENE THERAPY FOR ELONGATOR ACETYLTRANSFERASE COMPLEX SUBUNIT 1 (ELP1) | Non-Final OA | University of Massachusetts Chan School of Medicine |
| 18027067 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | Non-Final OA | The Johns Hopkins University |
| 18044923 | METHODS AND RELATED ASPECTS FOR PATHOGEN DETECTION | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18044568 | NOVEL TREATMENT REGIMEN FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | Non-Final OA | Merck Patent GmbH |
| 17655258 | COMPOSITION FOR TREATING HEPATITIS B, AND METHOD FOR EVALUATING REPLICATION ACTIVITY OF HEPATITIS B VIRUS | Final Rejection | RIKEN |
| 18000772 | MODIFIED ALPHAVIRUS FOR USE AS COVID-19 VACCINE | Non-Final OA | New York University |
| 18019547 | MULTIVALENT VACCINES AGAINST TURKEY ARTHRITIS REOVIRUS | Final Rejection | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18210829 | LIVE ATTENUATED ZIKA VIRUS WITH 3'UTR DELETION, VACCINE CONTAINING AND USE THEREOF | Non-Final OA | Board of Regents, The University of Texas System |
| 18017659 | TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH RESPIRATORY DISEASES | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 17957373 | METHODS FOR DETECTING NEUTRALIZING ANTIBODIES | Non-Final OA | Duke University |
| 17774329 | TREATMENT FOR PRIMARY AND METASTATIC CANCER | Final Rejection | Duke University |
| 17293861 | VECTORS COMPRISING A NUCLEIC ACID ENCODING LYSOSOMAL ENZYMES FUSED TO A LYSOSOMAL TARGETING SEQUENCE | Non-Final OA | ASKBIO INC. |
| 17917058 | ASSAY TO DETECT VIRUS | Non-Final OA | CORNELL UNIVERSITY |
| 17996119 | CORONAVIRUS VACCINE COMPOSITIONS AND METHODS OF USE | Non-Final OA | Thomas Jefferson University |
| 17813762 | CANCER VACCINES AND METHODS OF TREATMENT USING THE SAME | Non-Final OA | Inovio Pharmaceuticals, Inc. |
| 17918184 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-ASSOCIATED INFECTION IN A PATIENT | Non-Final OA | HOSPICES CIVILS DE LYON |
| 18008701 | DEVICE AND METHOD FOR CAPTURING AND ANALYZING AIRBORNE ORGANISMS | Non-Final OA | Consejo Superior de Investigaciones Cientificas (CSIC) |
| 17417096 | COMPOSITIONS COMPRISING SELF-ASSEMBLING VACCINES AND METHODS OF USING THE SAME | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 18557247 | RECOMBINANT CEDAR VIRUS CHIMERAS | Non-Final OA | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. |
| 18406002 | ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) CAPABLE OF EFFECTIVELY TREATING EVEN METASTATIC CANCER WHILE ENSURING SAFETY, WITH EXPRESSION CONTROL SYSTEM PROVIDING OPTIMAL EXPRESSION LEVEL OF MOUNTED IMMUNOGENIC GENE | Non-Final OA | Kagoshima University |
| 18284025 | A SIRNA DRUG, A PHARMACEUTICAL COMPOSITION, A SIRNA-SMALL MOLECULE DRUG CONJUGATE, AND THE APPLICATION THEREOF | Non-Final OA | SIRNAOMICS BIOPHARMACEUTICALS (GUANGZHOU) CO., LTD. |
| 17822431 | COMPOSITIONS AND METHODS FOR THE DETECTION OF VIRUSES IN A BIOLOGICAL SAMPLE | Non-Final OA | Biomerica, Inc. |
| 18317386 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 | Final Rejection | SEMENTIS LIMITED |
| 18030956 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | Non-Final OA | DEVACELL, INC. |
| 18182844 | METHOD FOR THE CONCENTRATION OF MICROSCOPIC SUBSTANCES DERIVED FROM LIVING ORGANISMS, ENVIRONMENTS, OR FOODS | Non-Final OA | KTEN BIO INC. |
| 18003858 | GORILLA ADENOVIRUS NUCLEIC ACID- AND AMINO ACID-SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREOF | Non-Final OA | REITHERA SRL |
| 17801452 | TESTING FOR VIRUSES AND CELLULAR BIOMARKERS | Non-Final OA | HERO SCIENTIFIC LTD. |
| 17916577 | RNA MARKERS FOR DIAGNOSING INFECTIONS | Non-Final OA | MeMed Diagnostics Ltd. |
| 17956078 | CRISPR ASSAY FOR RAPID, ENHANCED SCREENING OF HPV-RELATED DISEASE | Non-Final OA | OncoGenesis, Inc. |
| 17295414 | PRODUCTION OF IMMOBILISED BACTERIOPHAGE | Non-Final OA | FIXED PHAGE LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy